1-6 of 6
Florence Raynaud
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, Alvaro Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence Raynaud, Ruth Riisnaes, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C. Porter, Toby Prout, Mona Parmar, Anna Zachariou, Alison Turner, Ben Jenkins, Stuart McIntosh, Ed Ainscow, Anna Minchom, Juanita Lopez, Johann de Bono, Robert Jones, Emma Hall, Natalie Cook, Bristi Basu, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4634–4641.
https://doi.org/10.1158/1078-0432.CCR-22-1268
Published: 01 November 2022
View article titled, A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Open the PDF for A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, Rebecca Kristeleit, Phillip Debnam, Matthew Tall, Adam Stewart, Florence Raynaud, Michelle Dawn Garrett, Martin Toal, Leon Hooftman, Johann Sebastian De Bono, Jaap Verweij, Ferry ALM Eskens
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2687–2694.
https://doi.org/10.1158/1078-0432.CCR-11-3165
Published: 30 April 2012
View article titled, A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

Simon Pacey, Richard H. Wilson, Mike Walton, Martin M. Eatock, Anthea Hardcastle, Anna Zetterlund, Hendrik-Tobias Arkenau, Javier Moreno-Farre, Udai Banerji, Belle Roels, Heidi Peachey, Wynne Aherne, Johan S. de Bono, Florence Raynaud, Paul Workman, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1561–1570.
https://doi.org/10.1158/1078-0432.CCR-10-1927
Published: 15 March 2011
View article titled, A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

Udai Banerji, Michael Walton, Florence Raynaud, Rachel Grimshaw, Lloyd Kelland, Melani Valenti, Ian Judson, Paul Workman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7023–7032.
https://doi.org/10.1158/1078-0432.CCR-05-0518
Published: 03 October 2005
View article titled, Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models
Open the PDF for Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy

Beatrice M. Seddon, Geoffrey S. Payne, Laura Simmons, Ruth Ruddle, Rachel Grimshaw, Siew Tan, Alison Turner, Florence Raynaud, Gavin Halbert, Martin O. Leach, Ian Judson, Paul Workman
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5101–5112.
Published: 12 November 2003
View article titled, A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy
Open the PDF for A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy in another window
Journal Articles

Validation of the Fluorinated 2-Nitroimidazole SR-4554 as a Noninvasive Hypoxia Marker Detected by Magnetic Resonance Spectroscopy

Beatrice M. Seddon, Ross J. Maxwell, Davina J. Honess, Rachel Grimshaw, Florence Raynaud, Gillian M. Tozer, Paul Workman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2323–2335.
Published: 01 July 2002
View article titled, Validation of the Fluorinated 2-Nitroimidazole SR-4554 as a Noninvasive Hypoxia Marker Detected by Magnetic Resonance Spectroscopy
Open the PDF for Validation of the Fluorinated 2-Nitroimidazole SR-4554 as a Noninvasive Hypoxia Marker Detected by Magnetic Resonance Spectroscopy in another window